Congressional collaboration on DTC device ads
This article was originally published in The Gray Sheet
Executive SummarySen. Herb Kohl, D-Wis., wants to work with Rep. Bart Stupak, D-Mich., on addressing direct-to-consumer medical device advertisements, "to determine if moratoriums or other proposed restrictions" might be necessary for ads for restricted devices, the Senator writes in a Sept. 26 letter to Stupak, who is chairman of the House Energy and Commerce Committee's oversight sub-panel. Kohl notes that Stupak and Rep. John Dingell, D-Mich., chairman of the House Energy Committee, have asked drug firms to consider a two-year moratorium on DTC ads for new prescription drugs, as recommended by the Institute of Medicine. Kohl held a hearing Sept. 17 on DTC ads for devices ("1The Gray Sheet" Sept. 22, 2008, p. 3)
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.